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Lung  cancer  is  the  leading  cause  of  cancer  death  worldwide,  accounting  for  more  deaths  than  breast,
prostate  and  colon  cancer  combined.  While  treatment  decisions  are  determined  primarily  by  stage,  the-
rapeutically  non  small  cell lung  cancer  (NSCLC)  has traditionally  been  treated  as  a  single  disease.  However,
recent  ﬁndings  have  led  to  the  recognition  of histology  and  molecular  subtypes  as  important  determinants
in  treatment  selection.  Identifying  the  genetic  differences  that  deﬁne  these  molecular  and  histological
subtypes  has  the  potential  to impact  treatment  and  as  such  is  currently  the  focus  of much  research.
Microarray  and  genomic  sequencing  efforts  have  provided  unparalleled  insight  into  the  genomes  of  lungistological  subtypes
NA
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cancer  subtypes,  speciﬁcally  adenocarcinoma  (AC)  and  squamous  cell carcinoma  (SqCC),  revealing  sub-
type  speciﬁc  genomic  alterations  and  molecular  subtypes  as well  as  differences  in cell  signaling  pathways.
In  this  review,  we  discuss  the  recurrent  genomic  alterations  characteristic  of AC and SqCC  (including
molecular  subtypes),  their  therapeutic  implications  and  emerging  clinical  practices  aimed  at  tailoring
treatments  based  on  a tumor’s  molecular  alterations  with  the  hope  of  improving  patient  response  and
The A
survival.
© 2013 
. Introduction
Lung cancer is the leading cause of cancer death in the world,
ith an estimated 251,760 new cases and 180,440 deaths in Canada
nd the U.S. in 2012 [1,2]. Despite recent advances in the ﬁeld,
he 5-year survival rate has failed to improve signiﬁcantly over
he last 30 years, and remains a meager 15%, largely due to lim-
tations in detection and treatment strategies [3]. Histologically,
ung cancer is classiﬁed into two broad categories; small-cell lung
ancer (SCLC), occurring in approximately 15% of patients and the
ore prevalent NSCLC, which accounts for approximately 85% of
ases [4]. NSCLC can be further divided into 3 major histological
ubtypes: adenocarcinoma (AC), squamous cell carcinoma (SqCC)
nd large cell carcinoma, with AC and SqCC accounting for over
0% of NSCLC cases [4]. Despite sharing many biological features,
ubtypes differ in their cell of origin, location within the lung, and
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growth pattern, suggesting they are distinct diseases that develop
through differential molecular mechanisms.
Until recently, NSCLC was  treated as a single disease with a “one
size ﬁts all” therapeutic approach due to the similar therapeutic
effects of conventional chemotherapeutic agents. However, with
the observation that subtypes display distinct patterns of genomic
alterations and evidence from clinical trials demonstrating that
tumor histology inﬂuences response rates, toxicity and progression
free survival of targeted drugs such as bevacizumab, pemetrexed
and epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKI’s), histology is now recognized as an important factor in
treatment selection. The development of targeted therapies, specif-
ically TKIs, which act as competitive inhibitors of the ATP binding
pocket, blocking downstream signaling have provided improve-
ments in therapeutic response and highlight the clinical beneﬁt
of identifying and targeting biologically relevant alterations [5,6].
As a result of the success of EGFR TKIs, and the profound clinical
beneﬁt of targeted therapies in other cancers including breast and
chronic myeloid leukemia, a number of targeted therapies against
other recurrent molecular alterations in NSCLC are currently in
development, and molecular classiﬁcation of tumors is becoming
increasingly important in treatment selection.
Open access under CC BY-NC-SA license. As the landscapes of genomic alterations and associated clini-
cal features have been extensively characterized in AC and SqCC,
this review will focus explicitly on the two  most predominant sub-
types of NSCLC. This article summarizes the spectrum of shared
SA license. 
180 L.A.  Pikor et al. / Lung Cancer 82 (2013) 179– 189
NSCLC
SCLC
Lun g Cancer
A
B
Never  Smokers
AC
SqCC
Other
Smokers
Unknown
EGFR
KRAS
HER2
PIK3CA
BRAF MET
MAP2K1
ALK
ROS RET
AC
Unknown
FGFR1
NRF2
AKT1
DDR2
PIK3CA MET
BRAF
SqCC
C
AC
SqCC
Other
AC
SqCC
LC
Other
Fig. 1. Lung cancer subtypes. (A) Evolution of histological subtyping of lung cancer. The designation other encompasses minor histologies which includes NSCLC NOS,
adenosquamous and sarcomatoid. (B) Composition of histological subtypes in lung cancer of smokers and never smokers. (C) Molecular subtypes of AC and SqCC. Only
hyperactive oncogenes that are mutually exclusive to one another and therapeutically targetable are displayed. Pie charts depict the proportions of the patient population
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nith a given histological or molecular subtype.
nd unique genetic alterations characteristic of AC and SqCC,
rom gene expression signatures and patterns of DNA methyla-
ion and copy number alterations to mutations and chromosomal
earrangements identiﬁed by genome sequencing. The therapeu-
ic implications of ‘actionable’ alterations and emerging practices
imed at creating a personalized approach to the treatment of lung
ancer and improving survival are also addressed.
. Histopathology of NSCLC
While all histological subtypes of lung cancer are associated
ith cigarette smoking, SqCC and SCLC (Fig. 1A), both of which arise
redominantly in the central airways are most strongly associated
ith a history of smoking. Within the last few decades, there has
een a dramatic shift in the global trends of lung cancer histology,
ith a steady decline in SCLC and SqCC such that AC is now the most
ommon subtype of lung cancer (Fig. 1B). These changes are largely
elieved to be due to widespread changes in cigarette composition
lower tar and nicotine content) which has led to a change in smok-
ng behavior with smokers smoking more frequently and inhaling
eeper in an attempt to achieve the same effect, causing tobacco
arcinogens to be deposited further into the lung periphery. AC,
ow accounts for roughly half of all lung cancer cases and typicallyarises  in the glandular epithelium of the lung parenchyma from
type II pneumocytes or clara cells whereas SqCC, which accounts
for ∼30% of lung cancer and originates from basal cells in the central
airways [7] (Fig. 1A). Large cell carcinomas (LCC), are a diverse group
of poorly or undifferentiated tumors with poor prognosis that can
have neuroendocrine features and can harbor components or AC,
SqCC or SCLC. In addition to these three main subtypes, there exists
a small subset of tumors with mixed, (sarcomatoid and adenosqua-
mous carcinomas) or not otherwise speciﬁed (NOS) histologies and
clinical characteristics that are indistinct from other subtypes. Due
to the therapeutic importance of distinguishing histological sub-
types, in 2011 the IASLC/ATS/ERS proposed new guidelines for the
pathological classiﬁcation of NOS tumors [7]. The application of
immunohistochemical panels containing a mixture of AC and SqCC
markers and EGFR and ALK mutation testing have reﬁned NSCLC
classiﬁcation, signiﬁcantly reducing the percent of NOS tumors
diagnosed [8,9]. The inclusion of additional molecular alterations
with evidence supporting a subtype speciﬁc pattern of alteration
(ex: FGFR1 ampliﬁcation and DDR2 mutation in SqCC) as well as
molecular proﬁling of less characterized subtypes such as LCC will
provide insight into the biology of these tumors and potentially
identify novel genetic alterations that could aid in further reﬁning
pathological diagnosis and classiﬁcation of NSCLC subtypes.
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Fig. 2. Differential patterns of alteration in AC and SqCC. (A) Frequency plot of copy number alterations across the entire human genome for 83AC (purple) and 12 SqCC (blue)
relative to matched non-malignant tissue. Solid vertical black lines indicate chromosome boundaries and dotted lines chromosome arm boundaries. The frequency of copy
gain  is depicted in the top panel, and copy loss in the bottom. The greatest regions of disparity include gain of 3q, loss of 3p, chromosome 4 and 5q in SqCC, and gain of 7p in
AC.  Simpliﬁed EGFR signaling pathway diagram depicting the frequency of disruption, prominent genomic mechanisms of alteration and corresponding expression in AC (B)
and  SqCC (C) using data from cbio portal. The color of the gene depicts the trend in expression; red: overexpression (OE), orange: predominant OE, but some underexpression
(UE), yellow: both OE and UE observed at a fairly equal frequency, light green: predominant UE but some OE, dark green: UE and empty: no change in expression. The
frequency of alteration is displayed below the gene name and the mechanisms of alteration are denoted by #, - and * for ampliﬁcation, homozygous deletion and mutation
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eferences to color in this ﬁgure legend, the reader is referred to the web version of
. Molecular features associated with cell lineage and
moking
Tumor  biology is highly inﬂuenced by the lineage and differenti-
tion state of tumor precursor cells, and lineage survival pathways
equired for normal development are often aberrantly activated as a
esult of genomic alterations promoting the continued survival and
roliferation of cancer cells [10]. Two such lineage survival onco-
enes have been identiﬁed in NSCLC; NKX2-1/TITF1 in AC [11] and
OX2 in SqCC [12]. NKX2-1 and SOX2 are transcription factors that
lay essential roles in lung development and the correct differentia-
ion of respiratory cell types [13–15]. Clinically, NKX2-1 along with
K7, mucin, Napsin A p63, p40 and CK5/6 are used as immunohis-
ochemical markers for histological subtyping [16–18]. Although
OX2 is not frequently used as an IHC marker, high expression
s associated with poorly differentiated tumors, which typically
ave a poorer prognosis [19]. In addition to these two  lineagetus between subtypes include PIK3CA, JAK1 and KRAS. (For interpretation of the
rticle.)
speciﬁc  oncogenes, Lockwood et al., identiﬁed a squamous speciﬁc
oncogene, BRF2, located in a chromosome region of frequent ampli-
ﬁcation in SqCC (Fig. 2A). Activation of BRF2 plays a key role in SqCC
tumorigenesis via an increase in Pol III mediated transcription and
is frequently altered in pre-neoplastic lesions, suggesting it is an
early event in SqCC development and a potential lineage speciﬁc
oncogene [20].
In  addition to the histological differences, cigarette smoking is
associated with speciﬁc clinical and genetic features. Never-smoker
lung cancer, which accounts for up to 25% of all lung cancers world-
wide [21] are more strongly associated with East Asian ethnicity,
female gender and AC histology. Genetically, never smokers are
associated with a higher prevalence of EGFR, PTEN, ALK, ROS1, and
RET alterations, whereas KRAS, TP53, BRAF, STK11, and JAK2/3 muta-
tions and hypermethylation of p16 and LGALS4 are more common
in smokers [22–25]. More recently smoking dependent differences
have been shown to extend beyond speciﬁc gene alterations, to
1  Cancer 82 (2013) 179– 189
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Table 1
Recurrent ampliﬁcations and deletions with known oncogenes and tumor suppres-
sors in lung cancer.
Chromosomal
region
Alteration Subtype Candidate
oncogene/TSG
1q21.2 Ampliﬁcation AC ARNT
3q26.3-q27 Ampliﬁcation SqCC SOX2 and PIK3CA
4q12  Ampliﬁcation SqCC PDGFRA
5p15.33 Ampliﬁcation AC TERT
7p11.2 Ampliﬁcation NSCLC EGFR
8q12 Ampliﬁcation SqCC BRF2 and FGFR1
9p21.3 Deletion NSCLC CDKN2A/B
10q23.31 Deletion NSCLC PTEN
12q15 Ampliﬁcation AC MDM2
14q13.33 Ampliﬁcation AC NKX2-1
17p Deletion NSCLC TP53
17q11.2 Deletion SqCC Nf182 L.A.  Pikor et al. / Lung
ifferential patterns of chromosomal aberrations and differences in
he proportion of tumor genomes affected by segmental genomic
lterations [26], lower mutational frequencies and higher rates
f transitions verse transversions in never smokers compared to
mokers [22,23]. Collectively, these ﬁndings support the notion
hat diverse genetic mechanisms underlie the development of lung
umors in smokers and never smokers within a single histological
ubtype, indicating smoking status is an important clinical variable
hat should be considered when comparing AC and SqCC.
.  Alterations of genes and pathways characterizing AC and
qCC
The histological differences and disparate clinical behaviors of
C and SqCC suggest distinct molecular mechanisms underlie these
henotypic differences. Subtype speciﬁc patterns of genomic alter-
tions have been observed across all ‘omics levels, however how
ey genes and pathways interact and are differentially disrupted
etween subtypes, which can have important therapeutic implica-
ions, has only recently begun to be assessed.
.1. Gene expression
Gene  expression signatures have shown the ability to deﬁne
nd distinguish histological subtypes, [27–31] morphological sub-
ypes within AC [27,28] and SqCC [32] as well as distinguish
umor from non-malignant tissue [33–36], yet their clinical utility
s limited due to the lack of overlap between subtype signa-
ures. Interestingly, functional overlap between subtype speciﬁc
ignatures has been observed, suggesting disruption of speciﬁc
athways is selected for rather than speciﬁc genes. Deregulation
f antioxidant proteins, detoxiﬁcation genes and overexpression
f cytokeratins and cytokeratin-regulatory genes (GSTT1, CEL, and
RDX6) often characterize SqCC tumors [27–31], whereas dis-
uption of surfactant-related and small airway-associated genes
SFTPA2, SFTPB, MUC1, and NAPSA) are typically altered in AC
27–30,37,38]. These functions are largely associated with the
istological properties of the cells or origin from which these sub-
ypes develop, further highlighting the contribution of histology to
umorigenesis.
.2. Copy number alterations
DNA  copy number alterations (CNAs) are a prominent mech-
nism of gene disruption in NSCLC [11,39–48]. Although very few
NAs are altered exclusively in a single subtype, many regions
re altered at signiﬁcantly different frequencies between subtypes
nd therefore deemed regions of subtype speciﬁc CNA (Fig. 2A
nd Table 1) [40,41,43]. For example, a recent analysis of over
000 tumors identiﬁed 13 subtype-speciﬁc regions with at least
 25% difference in the frequency of alteration between subtypes
49]. Amidst all copy number studies, the most prominent and
onsistent difference between subtypes is ampliﬁcation of 3q in
qCC (Fig. 2A) [12,39,40,42,44,46,48,50].
.3.  Whole genome sequencing
Advances  in exome and whole genome sequencing technolo-
ies have enabled high throughput identiﬁcation of mutations, copy
umber aberrations, and structural alterations such as gene fusions
nd chromosomal rearrangements in a genome-wide, unbiased
anner. One of the ﬁrst high throughput sequencing studies of lung
ancer interrogated 623 cancer related genes in 188 AC samples and
dentiﬁed over 1000 somatic mutations and 26 frequently mutated
enes. These included genes known to be frequently mutated in
ung cancer such as TP53, BRAF, ERBB2, KRAS, STK11, EGFR, PIK3CA,17q12 Ampliﬁcation AC ERBB2
19p Deletion AC STK11/LKB1
PTEN and CDKNA, in addition to NF1, RB1, ATM, FGFR4, and ERBB4
which had no previous evidence of recurrent mutation in lung can-
cer [51]. Since then, sequencing of AC and matched non malignant
tissue has continued to identify novel mutations and gene fusions
(including ARID1A, SMARA4, ASH1L, U2AF1 and KIF5B-RET) while
simultaneously revealing immense mutational heterogeneity both
within (intra) and between (inter) patients [23,52–54]. For exam-
ple, a single AC tumor was found to have over 50,000 variants,
of which 391 affected coding sequences [55]. Substantial inter-
and intra-tumoral heterogeneity has also been observed in copy
number and gene expression proﬁling of AC, suggesting the mech-
anisms underlying tumorigenesis in this subtype may be extremely
diverse. Whether this heterogeneity could be due in part to the
histological subgroups of AC, or some other feature has yet to be
elucidated.
To date, the most comprehensive sequencing analysis of SqCC
was performed by the Cancer Genome Atlas (TCGA) research net-
work. In addition to the identiﬁcation of a number of frequently
mutated genes; TP53, CDKN2A, PTEN, PIK3CA, KEAP1, MLL2, HLA-A,
NFE2L2, NOTCH1 and RB1, their analysis identiﬁed 360 exonic muta-
tions, 165 genomic rearrangements, and an average of 323 CNAs
per sample [50]. While mutation patterns speciﬁc to AC and SqCC
have emerged, analogous to CNA few are exclusive to a single sub-
type and many, LRRC7, SLC7A13, PCDH11X, CSMD3, DNAH3, CD1B,
CACNA2D1, KEAP1, PIK3C2B and CTNNA3 for example, occur at sim-
ilar frequencies in both subtypes [56]. Interestingly, SqCC genomes
were found to have a signiﬁcantly higher rate of CNAs and muta-
tions than all other tumor types (glioblastoma multiforme, ovarian,
colorectal, breast and renal cell carcinoma) proﬁled by the TCGA
thus far. High mutation rates have also been observed in AC [57],
suggesting lung cancers as a whole are more genetically unstable,
which could be due to the carcinogenic effects of cigarettes. Stud-
ies aimed at identifying genes driving AC and SqCC phenotypes
must therefore consider the highly complex genomic backgrounds
of these tumors when deciphering biologically and therapeutically
relevant alterations. Taken together, these studies highlight the
heterogeneity and genomic complexity of lung cancer subtypes.
Expected to be released this year, the TCGA’s characterization of
AC will provide a similar in depth description of the spectrum of
alterations in AC and allow for a comprehensive multidimensional
comparison between AC and SqCC.
4.4. DNA methylationEpigenetic marks such as DNA methylation are important
regulators of somatically heritable changes in gene expression.
DNA methylation is a tissue-speciﬁc and inherently reversible gene
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egulatory alteration targeted for chemoprevention and treat-
ent and as potential diagnostic and prognostic biomarkers in
alignant and non-malignant tissues [58]. DNA methylation pro-
ling of NSCLC has identiﬁed hundreds of aberrantly methylated
enes [59–63]. However, to date most genome-wide epigenetic
tudies lack corresponding gene expression level data, which
n the context of determining functional consequences of DNA
ethylation alterations to lung cancer biology, is limiting. In SqCC,
ntegration of global DNA methylation and expression proﬁles
ndicate a role for aberrant DNA methylation in DNA replication,
ecombination and repair functions, and that methylation of
OXA2 and HOXA10 may  have prognostic relevance [64,65]. In AC,
berrantly methylated genes are enriched for cell differentiation,
ell cycle regulation, epithelial to mesenchymal transition and RAS
nd WNT  signaling pathways [66].
.5. Non-coding RNAs
The  human genome contains approximately 20,000 protein-
oding genes, representing <2% of the genome [67]. Within the
ast decade sequencing technologies have revealed that over 90%
f the genome is actively transcribed and includes a collection of
ntisense and non-coding RNA (ncRNA) transcripts [68,69]. ncRNA
re transcripts that lack open reading frames and do not typ-
cally encode a protein, the best studied of which are miRNA.
imilar to gene expression, miRNA signatures can accurately sepa-
ate histological subtypes and are thought to be as good or even
uperior to global mRNA expression proﬁles in their ability to
ccurately classify NSCLC subtypes [70]. miR-205 has been shown
s a highly speciﬁc marker for SqCC [71], while in AC, speciﬁc
iRNAs have been shown to associate with mutation patterns.
iR-155 is upregulated exclusively in AC with wildtype EGFR and
RAS, while miR-21 and miR-25 are upregulated in EGFR mutant
C and miR-495 is up-regulated in KRAS positive AC [72,73]. The
tudy of long ncRNAs (lncRNAs) in lung cancer is still an emerg-
ng ﬁeld, and to date no lncRNAs have demonstrated diagnostic or
herapeutic potential in lung cancer. However, diagnostic lncRNAs
ave been identiﬁed in other cancer types including prostate and
iver cancer [74,75] and metastasis-associated lung adenocarcinoma
ranscript 1 (MALAT1) is known to be associated with metasta-
is and poor prognosis in NSCLC, highlighting its potential as a
rognostic marker [76]. Based on these and other recent ﬁndings,
on-coding transcripts may  be just as important to tumor biology
nd therapeutics as protein coding transcripts, underscoring their
igniﬁcance.
.6. Pathways associated with subtype speciﬁc genomic
lterations
While the application of single dimensional analyses (expres-
ion, copy number, or mutation studies alone) are informative for
dentifying disrupted genes, they often overlook genes disrupted at
ow frequencies and are not capable of distinguishing causal from
assenger events [77]. The integration of multiple dimensions of
omics data provides a more comprehensive understanding of the
enetic mechanisms affecting a tumor as it not only enables the
dentiﬁcation of genes with concurrent DNA and expression alter-
tions which are more likely to be driver alterations, but also genes
isrupted by multiple mechanisms but at low frequencies by any
ingle mechanism (Fig. 2B and C) [77]. However, gene discovery
n its own provides limited information regarding tumor biology.
he inclusion of pathway or network analysis (Ingenuity Pathway
nalysis, Kyoto Encyclopaedia of Genes and Genomes (KEGG) and
ene Set Enrichment Analysis to name a few) can be a useful tool
o provide biological context to a set of alterations and aid in inter-
reting how they work in conjunction to promote tumorigenesisr 82 (2013) 179– 189 183
(Fig.  2B and C). Furthermore, understanding where a pathway is dis-
rupted can reveal novel therapeutic intervention points that may
help achieve better therapeutic response.
Numerous studies mapping multiple omics dimensions to
annotated pathways and cancer hallmarks support the notion
that alterations work in concert to selectively deregulate path-
ways and further conﬁrm that AC and SqCC develop through
distinct oncogenic pathways [11,50,51,65]. Single subtype analy-
ses have identiﬁed several affected pathways/hallmarks including;
focal adhesions, cell cycle, activation of the JAK/STAT pathway and
sustainment of proliferation in AC [22,52] and oxidative stress
response, squamous differentiation and deregulation of the PI3K
pathway in SqCC [51]. Of therapeutic relevance, was  the ﬁnding
that ∼70% of SqCC tumors had alterations in one of the PI3K/AKT,
receptor tyrosine kinase, or RAS pathways, however the optimal
intervention points of these pathways are still under investiga-
tion. Work by our group comparing AC and SqCC identiﬁed 778
subtype-speciﬁc genes (altered by CNA or DNA methylation and a
two-fold expression change) which were found to differentially dis-
rupt cellular pathways and networks, including down-regulation of
the HNF4alpha pathway in AC and disruption of histone modifying
enzymes and the E2F1 transcription factor in SqCC [65]. Differential
pathway activation of the cell cycle in AC, and DNA repair in SqCC,
have been reported along with differences in multiple metabolic
pathways [78].
4.7.  Therapeutic implications
With  distinct patterns of genetic disruption underscoring tumor
development, it is unrealistic to assume AC and SqCC would have
similar responses to all chemotherapies, especially those target-
ing speciﬁc proteins. Both bevacizumab, a monoclonal antibody
against vascular endothelial growth factor (VEGF) and pemetrexed,
an antifolate chemotherapy that targets thymidylate synthetase
(TS) are contraindicated in SqCC due to an increased risk of
pulmonary hemorrhage and reduced survival times, respectively
[79–81]. TS gene expression has been shown to be predictive
of pemetrexed efﬁciency [82,83] and is elevated in SqCC com-
pared to AC, providing an explanation for the reduced efﬁcacy
in these patients [81,84]. In silico screening of compounds capa-
ble of “reversing” gene expression signatures has been shown to
identify compounds with subtype speciﬁc efﬁcacy. For example,
treatment of lung cancer cell lines with the HDAC inhibitor Tricho-
statin A, revealed SqCC lines were signiﬁcantly more sensitive than
AC lines [65]. These ﬁndings highlight the potential importance
of information about the underlying biology to inform decisions
regarding treatment regimes, such that treatments can be tailored
to the individual to potentially improve patient response and sur-
vival.
5. Targetable genetic alterations
The discovery of improved responses and outcomes with EGFR
TKIs in lung cancer patients harboring EGFR mutations launched
the search for additional actionable alterations and marked the
beginning of a new era in which NSCLCs are deﬁned by their driver
alterations (Fig. 1). To date only one other targeted agent, a small
molecule inhibitor of ALK (crizotinib) has been approved for clin-
ical use, however more than a dozen other targeted therapies are
currently being assessed in clinical trials. Table 2 lists the most com-
mon  actionable alterations identiﬁed in NSCLC along with targeted
agents developed against them and a brief description about their
mechanism of action. Speciﬁc details of these inhibitors have been
extensively reviewed elsewhere [85–89].
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Table 2
Molecular subtypes of lung cancer.
Gene Location Frequency
%AC
Frequency
%  SqCC
Alteration Clinical features Drug sensitivity References
EGFR 7p12 10–15 <5 del exon 19, L858R AC, AS, F, NS Geﬁtinib* and Erlotinib* [6,135–138]
KRAS  12p12.1 21 6 Mutation of amino acid
12  and 13
AC,  F, Y, CS None [97,138]
MEK1  15q22.1 1 N/A E56P, K57N, D67N AC Selumetinib (2), Trametinib (2) [87,139,140]
HER2  17q12 <5 Rare Exon 20 Insertion AC, AS, F, NS Neratinib (2), Afatinib (3),
Trastuzumab (3)
[87]
ALK  2p23 4–6 Rare EML4 or KIF5B fusion AC, Y, NS AP26113 (2), Ganetespib (2),
LDK378 (2), CH5424802 (2),
Sunitinib (2), Crizotinib*
[101–104,141–143]
ROS  6q22 1–2 N/A Fusion with multiple
genes
AC,  Y, NS Crizotinib (c + 1 patient) [22,23,111,144–148]
RET  10q11.2 1–2 N/A Fused with KIF5B,
CCDC6,  or NCOA4
AC,  NS Vandetanib (2), Sunitinib (c),
Sorafenib (c), Cabozantinib (2),
Lenvatinib (2), Ponatinib (2)
[54,88,107–111,149,150]
PDGFRA 4q12 3–7 8–12 Ampliﬁcation SqCC Sorafenib (3), Sunitinib,
Crenolanib  (2), pazopanib (2),
Axetinib (2)
[151,152]
FGFR1  8p12 1 16–20 Ampliﬁcation SqCC Dovitinib (2), PD173074 (v),
AZD4547 (2)
[12,153–155]
NRF2  2q31 1–2 10–15 Mutation Exon 2 SqCC None [50,156–159]
DDR2  1q23.3 1 4 Mutation SqCC Dasatinib (2), Nilotinib (c),
Imatinib (c)
[160–162]
AKT1  14q32.32 0 6 E17K SqCC MK2206 (2) [100,163,164]
PIK3CA  3q26.3 1–3 3–7  E542K, E545K, H1047R None XL147 (2), BKM120 (2) [87,100,165,166]
PIK3CA  3q26.3 6 33 Ampliﬁcation None None [87,165–167]
BRAF  7q34 2 1–3 G465V and L596R None Vemurafenib (2), Dasatinib (2),
Dabrafenib (2)
[97,98,163,168,169]
PTEN  10q23.3 8–20 8–20 Deletion None None [170,171]
PTEN  10q23.3 2 10 Mutation exon 9,20 None None [138,172]
MET  7q31 3–21 3–21 Ampliﬁcation None Tivantinib (2), Onartuzumab
(3),  SU11274 (c)
[11,163,173–175]
MET  7q31 <5 <5 Mutation exon 14 None Tivantinib (2), OSU11274 (c) [87,163,173,176]
STK11  19p13 13–34 5–19 Exon 1 mutation C, CS None [177,178]
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aS: Asian, C: Caucasian, M:  male, F: female, NS: never smoker, CS: current smoker, 
:  FDA approved, 2: Phase 2 trial, 3: Phase 3 trial, c: in vitro evidence, v: in vivo evid
.1. AC predominant alterations
EGFR  and KRAS mutations along with EML4-ALK fusions are
he three most frequent driver alterations in AC, occurring with
utual exclusivity in approximately 35–40% of tumors (Fig. 1C and
able 2). Clinically, EGFR mutations are more prevalent in Asian
emale never smokers and are associated with a better prognosis
hile KRAS mutations are predictive of poor outcome, resistance
o EGFR TKIs and are more common in smokers and Caucasians
90]. While there are currently no approved therapeutic agents for
RAS mutant tumors due to the difﬁculty of targeting KRAS itself,
nd debate surrounds whether KRAS should be included in molec-
lar diagnostic panels [91] a number of combination therapies have
ecently shown efﬁcacy in KRAS mutant tumors. In murine models
f lung cancer, the combination of the MEK  inhibitor (selumitinib)
ith either a BCL-XL (navitoclax) or PI3K (NVP-BKM120) inhibitor
esulted in marked tumor regression, while in a randomized phase
I study, the combination of selumetinib and docetaxel showed
 clinical beneﬁt in KRAS mutant tumors compared to placebo
92–94]. Despite the previous difﬁculties of targeting KRAS, these
ndings suggest that therapies targeting the multiple critical effec-
ors of KRAS are effective and that targeted therapies for KRAS may
oon be available. Other driver genes preferentially mutated in AC,
ut at a signiﬁcantly lower frequency (1–4%) include HER2 and
AP2K1/MEK1 (Table 2) which are mutually exclusive of, PIK3CA,
RAF, EGFR and KRAS mutations [87]..2. SqCC predominant alterations
Fewer actionable alterations have been identiﬁed in SqCC and
s a result targeted therapies for SqCC alterations have yet to beng adult.
approved  for clinical use. Recurrent alterations characteristic of
SqCC include ampliﬁcation of SOX2, PIK3CA, PDGFRA and FGFR1 as
well as mutation of DDR2, AKT1 and NRF2 (Fig. 1C) [95]. Despite
a high frequency of SOX2 and PIK3CA ampliﬁcation (20–30% of
cases), drugs targeting these alterations are not currently avail-
able. However, SOX2 inhibitors and inhibitors with activity against
PIK3CA mutations such as NVP-BKM120, are currently under devel-
opment. BMK120 is currently in phase II trials (NCT01297491)
and is therefore one of the most advanced SqCC speciﬁc targeted
therapies in development [96]. While inhibitors targeting, PDGFRA
FGFR1, DDR2 and AKT1 are being development, clinical trials specif-
ically enrolling lung SqCC patients with FGFR1, PDGFRA and DDR2
mutations have not yet been reported. Recently, IGF1R and EphA2
have emerged as potential therapeutic targets in SqCC [95], how-
ever drug speciﬁcity issues have hindered development of targeted
agents against these alterations and as such they are not currently
considered molecular subtypes.
5.3. Alterations common to both subtypes
Many alterations are observed at similar frequencies in both
AC and SqCC (Table 2 and Fig. 1C), including TP53, BRAF, PIK3CA,
MET and STK11 mutations, loss of PTEN and ampliﬁcation of
MET, with BRAF, PIK3CA, and MET  inhibitors already in develop-
ment/trials. Although FDA approved targeted therapies against
BRAF exist for the treatment of melanoma, only 10% of BRAF muta-
tions in lung cancer are V600E, thus limiting the utility of most
existing BRAF inhibitors [97,98]. Mutation of TP53 is the most
common mutation in both subtypes, occurring in more than 50%
of samples, however, targeting TP53 is inherently difﬁcult due to
the wide range of mutant proteins that exist and the multitude
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f complex protein–protein interactions. Few effective targeted
herapeutics against tumor suppressor genes exist, as they are sig-
iﬁcantly more difﬁcult to target than a hyperactive oncogenes,
lthough it is thought PTEN may  be targetable in the near future
99,100].
.4. Gene fusions
While  gene fusions have been observed in both subtypes, they
re more frequently found in AC (Fig. 1C). EML4-ALK translocations
re the result of a small inversion within the short arm of chromo-
ome 2 occurring in 3–7% of NSCLC [101–104]. To date more than
4 different EML4-ALK fusion variants have been identiﬁed [101],
onferring resistance to EGFR TKIs, but sensitivity to ALK inhibitors
uch as crizotinib [105,106]. ROS1 fusions are present in 1–2% of
atients and have more than 10 different fusion partners (Table 2).
reliminary studies indicate that crizotinib has activity against
OS, however additional testing is still needed before crizotinib
s approved for use in patients with ROS fusions. RET fusions, the
ewest class of gene fusion in lung cancer, are observed in 1–2% of
atients, and typically involve fusion with KIF5B [54,88,107–113].
ET-KIF5B fusions are found predominantly in AC of never smokers
nd are mutually exclusive with mutations in EGFR, KRAS and ALK
usions [108,110,111]. Vandetanib, a multi-kinase inhibitor with
nti-RET activity, has been approved by the FDA based on its efﬁ-
iency in medullary thyroid carcinoma but its effectiveness in lung
ancer is currently unknown [114]. Serine-threonine kinase and
on-protein kinase fusions have also been identiﬁed in NSCLC, but
nly in single samples [23].
.5. Clinical impact of targeted therapies
The success/beneﬁts of targeted therapy have highlighted the
mportance of deﬁning the molecular alterations within a tumor as
ell as histology. However, despite initial responses and improved
utcomes associated with targeted therapies, the majority of
atients develop resistance within a year or two, and all relapse,
uch that targeted agents for lung cancer are administered without
urative intent. As such primary and acquired resistance remain
ajor obstacles to the successful treatment of lung cancer. Mech-
nisms of resistance include, but are not limited to additional gene
utations, (ex: T790M in EGFR and L1196M and G1269A in ALK)
ene ampliﬁcation of the target and other genes (ex: MET), sub-
ype conversion (NSCLC to SCLC) and activation of other signaling
athways, such as KIT, KRAS which act as a bypass mechanisms
115–117]. For EGFR TKIs, T790M mutations and MET  ampliﬁca-
ion are the most common mechanisms of resistance, occurring
n roughly 60% of cases, whereas for ALK, secondary mutations
ave been described in 30% of cases with resistance. A number
f strategies to overcome resistance to targeted therapies have
een developed. These include MEK  [118] and heat shock pro-
ein inhibitors [119] to reverse acquired resistance to geﬁtinib
nd crizotinib respectively, dual kinase inhibitors such as lapa-
inib which targets both EGFR and HER2 and have demonstrated
ffectiveness in breast tumors [120], and multidrug/multi-pathway
argeting approaches [121]. Substantial effort has been directed
oward overcoming resistance to therapy, and the speciﬁc details
egarding mechanisms of resistance to TKIs, strategies to overcome
esistance and development of second/third generation targeted
herapies are reviewed in great detail elsewhere [117,121–124].
he application of repeat biopsies over the course of treatment is
n ideal approach to studying mechanisms of resistance. However
ue to the practical limitations of repeat biopsies, this type of study
s rare. The use of surrogate specimens such as tumor cells from
alignant pleural effusions (MPE) (which occur in 15% of patients
ith advanced NSCLC) represents a possible alternative to repeatr 82 (2013) 179– 189 185
biopsies  [125]. Pleural effusion ﬂuid can be easily collected through
relatively non-invasive procedures throughout the course of treat-
ment and previous studies have shown high concordance between
tumor and MPE  tumor cell mutations [126]. Moreover, chemother-
apy has been show to reach the pleural cavity, indicating tumor cells
from MPE  could be an extremely useful for studying mechanisms
of resistance [127].
Notably,  genomic proﬁling of SCLC has also revealed frequent
alterations, e.g. P53, RB1 and EZH2, raising the potential of future
development of targeted therapies blurring the separation of SCLC
as a separate entity in the context of treatment design [128–130].
6.  Emerging clinical practices
With the continued development of novel targeted therapeutics,
genomic analyses of patient tumors to inform treatment selection
will become routine clinical practice. However, due to the cur-
rent costs of generating a complete tumor proﬁle, most institutions
only test for the most prominent alterations with indications for
approved targeted therapies: KRAS and EGFR mutations and EML4-
ALK fusions. Moving toward personalizing treatment, some of the
major academic cancer centers have developed efﬁcient, cost effec-
tive tumor genotyping protocols to screen patients for all actionable
alterations, a few of which are discussed below.
The Biomarker-integrated Approaches of Targeted Therapy for
Lung Cancer Elimination (BATTLE) trial completed in 2011, inte-
grated real time molecular data in a clinical trial to identify
speciﬁc patient populations likely to beneﬁt from individualized
treatment [131]. BATTLE established the feasibility of performing
biopsies and real time biomarker analysis, and validated pre-
speciﬁed hypotheses regarding biomarkers and targeted agents
while also identifying potential new predictive markers, thereby
making substantial progress in the practice of personalized lung
cancer treatment [131]. At Memorial Sloan Kettering, the Lung
Cancer and Squamous Mutation Analysis Projects (LC-MAP and SQ-
MAP) used multiplexed mass-spectrometry to test for alterations
in targetable pathways, speciﬁcally EGFR, KRAS, NRAS, BRAF, HER2,
PIK3CA, MEK1, AKT1, PTEN, DDR2 mutations, EML4-ALK fusions and
FGFR1 ampliﬁcation [132,133].
Building on the success of these initiatives and using the latest
next-generation sequencing technology, MSKCC and MD  Anderson
have developed new cancer genomics pipelines; Integrated Muta-
tion Proﬁling of Actionable Cancer Targets (IMPACT) which involves
targeted exon sequencing of 275 cancer genes [134] and the Moon
Shot Program which integrates early detection, smoking cessation,
and genomic proﬁling with targeted drug discovery/repositioning
(http://cancermoonshots.org/moon-shots/lung/). These compre-
hensive, high throughput approaches enable the detection of
copy number alterations, genomic rearrangements and mutations
with high coverage and sensitivity. Using these approaches, the
therapeutic strategy with the greatest potential beneﬁt can be
administered to the patient, whether approved for clinical use or
still in trial, bringing personalized treatment of lung cancer closer
to reality.
Despite this progress, much work remains before genome char-
acterization can be implemented into routine clinical decision
making. Optimization of technologies, computational analysis and
biological interpretation of sequencing results (passenger vs. driver
mutations) in an efﬁcient, cost effective manner with clinically
useful turnaround times remain major challenges. With several
different types of alterations to test for (deletions, insertions, muta-
tions, ampliﬁcations and fusions) and more than a dozen actionable
targets, a high throughput, highly sensitivity method is required.
Moreover, technologies should be suitable for routine clinical spec-
imens, some of which such as ﬁne needle aspirates or biopsies can
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ave low tumor cell content. Although it is unlikely that cancer
enome sequencing will ever serve as the exclusive test upon which
linical decisions are made, it may  prove to be a powerful diagnos-
ic and prognostic tool for guiding therapeutic decision making in
he future.
.  Conclusion
The discovery and success of targeted therapies has launched a
ew era of lung cancer research focused on the detection and treat-
ent of targetable alterations. Despite the continued identiﬁcation
f new driver alterations, half of NSCLC cases have no detected
ctionable alterations, and even for those targetable alterations,
rug design and resistance remain major limitations to success-
ul, curative treatment of lung cancer. While sequencing efforts
ontinue to identify novel mutations in NSCLC, it is unlikely point
utations will characterize all tumors, emphasizing the need to
ook beyond protein coding genes, to ncRNAs and DNA methyla-
ion and how these different transcripts and alterations cooperate
o deregulate pathways and signaling networks. Ongoing efforts
oward further deﬁning the landscape of genetic alterations in AC
nd SqCC and tumor heterogeneity will continue to improve our
nderstanding of lung cancer biology, yielding novel therapeutic
nd diagnostic targets capable of improving the survival of NSCLC.
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